No­var­tis-backed Io­n­is sub­sidiary Akcea maps a $100M IPO as it steers a lead drug to reg­u­la­tors

Over the last three months Io­n­is sub­sidiary Akcea has ex­e­cut­ed a $1.65 bil­lion part­ner­ship with No­var­tis on two of its four drugs and mapped a path to reg­u­la­tors on both sides of the At­lantic af­ter its lead ther­a­py volane­sors­en suc­cess­ful­ly com­plet­ed a Phase III study. And now Akcea — a spe­cial­ist in lipid dis­or­ders — is shoot­ing for a $100 mil­lion IPO, with No­var­tis com­ing in to sup­port the move with an ex­tra $50 mil­lion to pur­chase a grow­ing eq­ui­ty stake.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.